FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2884685998> ?p ?o ?g. }

• W2884685998 endingPage "2300" @default.
• W2884685998 startingPage "2293" @default.
• W2884685998 abstract "Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia Ilana R Yurkiewicz,1 Lori Muffly,2 Michaela Liedtke1 1Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA, USA; 2Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, USA Abstract: Despite improved rates of remission and cure in newly diagnosed adult acute lymphoblastic leukemia (ALL), the prognosis for patients with relapsed or refractory disease remains poor and the 5-year overall survival rate after relapse is under 10%. A recent paradigm shift has focused on the promise of targeted immunotherapy rather than standard chemotherapy, as ALL blast cells express a variety of antigens, and monoclonal antibodies may be developed to identify and destroy the leukemic cells. Inotuzumab ozogamicin is a CD22 monoclonal antibody conjugated to the cytotoxic antibiotic calicheamicin. CD22 expression is detected on leukemic blasts in over 90% of patients with ALL. Based on promising results from preclinical studies, inotuzumab ozogamicin was tested in Phase 1/2 and Phase 3 clinical trials and it demonstrated improved complete remission rates, progression-free survival and overall survival in relapsed or refractory adult ALL compared to standard therapy. Ongoing studies are evaluating the value of inotuzumab ozogamicin when given in combination with chemotherapy as part of upfront treatment. This review discusses the drug’s biochemical properties and mechanism of action, preclinical research outcomes, clinical trial results, adverse events and toxicities, drug approval and ongoing investigations. Keywords: acute lymphoblastic leukemia, relapsed/refractory, inotuzumab ozogamicin, monoclonal antibody–drug conjugate, CD22" @default.
• W2884685998 created "2018-08-03" @default.
• W2884685998 creator A5003368910 @default.
• W2884685998 creator A5023853700 @default.
• W2884685998 creator A5085783292 @default.
• W2884685998 date "2018-07-01" @default.
• W2884685998 modified "2023-10-16" @default.
• W2884685998 title "Inotuzumab ozogamicin: a CD22 mAb&ndash;drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia" @default.
• W2884685998 cites W1488000644 @default.
• W2884685998 cites W1537235822 @default.
• W2884685998 cites W1600925615 @default.
• W2884685998 cites W1964449492 @default.
• W2884685998 cites W1966771497 @default.
• W2884685998 cites W1972172571 @default.
• W2884685998 cites W1977380325 @default.
• W2884685998 cites W1991404956 @default.
• W2884685998 cites W2002862326 @default.
• W2884685998 cites W2005419063 @default.
• W2884685998 cites W2035343180 @default.
• W2884685998 cites W2043649175 @default.
• W2884685998 cites W2052739233 @default.
• W2884685998 cites W2057680307 @default.
• W2884685998 cites W2066508515 @default.
• W2884685998 cites W2075275816 @default.
• W2884685998 cites W2077086197 @default.
• W2884685998 cites W2081127271 @default.
• W2884685998 cites W2083001039 @default.
• W2884685998 cites W2106275447 @default.
• W2884685998 cites W2113426218 @default.
• W2884685998 cites W2126855868 @default.
• W2884685998 cites W2127742735 @default.
• W2884685998 cites W2128491464 @default.
• W2884685998 cites W2150235363 @default.
• W2884685998 cites W2151348405 @default.
• W2884685998 cites W2161054245 @default.
• W2884685998 cites W2271661112 @default.
• W2884685998 cites W2295805773 @default.
• W2884685998 cites W2419639370 @default.
• W2884685998 cites W2497172912 @default.
• W2884685998 cites W2520695016 @default.
• W2884685998 cites W2591709377 @default.
• W2884685998 cites W2725721905 @default.
• W2884685998 cites W2725925241 @default.
• W2884685998 cites W2725970815 @default.
• W2884685998 cites W2730231599 @default.
• W2884685998 cites W2745522463 @default.
• W2884685998 cites W2752517775 @default.
• W2884685998 cites W2760141948 @default.
• W2884685998 cites W2782994300 @default.
• W2884685998 cites W2787621143 @default.
• W2884685998 cites W2790768260 @default.
• W2884685998 doi "https://doi.org/10.2147/dddt.s150317" @default.
• W2884685998 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6063246" @default.
• W2884685998 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30087554" @default.
• W2884685998 hasPublicationYear "2018" @default.
• W2884685998 type Work @default.
• W2884685998 sameAs 2884685998 @default.
• W2884685998 citedByCount "45" @default.
• W2884685998 countsByYear W28846859982019 @default.
• W2884685998 countsByYear W28846859982020 @default.
• W2884685998 countsByYear W28846859982021 @default.
• W2884685998 countsByYear W28846859982022 @default.
• W2884685998 countsByYear W28846859982023 @default.
• W2884685998 crossrefType "journal-article" @default.
• W2884685998 hasAuthorship W2884685998A5003368910 @default.
• W2884685998 hasAuthorship W2884685998A5023853700 @default.
• W2884685998 hasAuthorship W2884685998A5085783292 @default.
• W2884685998 hasBestOaLocation W28846859981 @default.
• W2884685998 hasConcept C10205521 @default.
• W2884685998 hasConcept C111700020 @default.
• W2884685998 hasConcept C126322002 @default.
• W2884685998 hasConcept C142424586 @default.
• W2884685998 hasConcept C143998085 @default.
• W2884685998 hasConcept C159654299 @default.
• W2884685998 hasConcept C176290653 @default.
• W2884685998 hasConcept C194409129 @default.
• W2884685998 hasConcept C203014093 @default.
• W2884685998 hasConcept C2776694085 @default.
• W2884685998 hasConcept C2777325958 @default.
• W2884685998 hasConcept C2778020697 @default.
• W2884685998 hasConcept C2778245361 @default.
• W2884685998 hasConcept C2778461978 @default.
• W2884685998 hasConcept C2778623314 @default.
• W2884685998 hasConcept C2781107101 @default.
• W2884685998 hasConcept C28328180 @default.
• W2884685998 hasConcept C2909962599 @default.
• W2884685998 hasConcept C542903549 @default.
• W2884685998 hasConcept C54355233 @default.
• W2884685998 hasConcept C71924100 @default.
• W2884685998 hasConcept C86803240 @default.
• W2884685998 hasConcept C87355193 @default.
• W2884685998 hasConceptScore W2884685998C10205521 @default.
• W2884685998 hasConceptScore W2884685998C111700020 @default.
• W2884685998 hasConceptScore W2884685998C126322002 @default.
• W2884685998 hasConceptScore W2884685998C142424586 @default.
• W2884685998 hasConceptScore W2884685998C143998085 @default.
• W2884685998 hasConceptScore W2884685998C159654299 @default.
• W2884685998 hasConceptScore W2884685998C176290653 @default.

• next